Holmlin, Erik, PhD


CEO, BioNano Genomics

Erik Holmlin has two decades of experience in the life science and health care industries. His expertise spans technology development and commercialization, global marketing, commercial operations, venture financing, mergers & acquisitions and intellectual property.

Recently, he served as president and CEO of GenVault Corporation, a life science company bringing innovative solutions to biosample management. He merged GenVault with IntegenX, Inc. in January of 2011. He also served as an entrepreneur in residence (EIR) at Domain Associates, LLC, a leading dedicated life science venture-capital firm. Prior to these roles, Erik was chief commercial officer at Exiqon A/S, where he was responsible for global sales, marketing, and clinical affairs for two businesses: Oncology Services in a CLIA lab and Consumables Business in Life Sciences Research.

In 2001 Mr. Holmlin led the formation of GeneOhm Sciences, Inc., for which, over a span of 5 years, he was director of chemistry, senior technology director, vice president of technology and business development, and vice president of marketing.

At GeneOhm, he also led or participated in securing three rounds of venture financing and in the acquisition of Infectio Diagnostics, Inc., and orchestrated GeneOhm's acquisition in 2006 by Becton Dickinson. As an executive at BD, he then served as vice president of marketing and development, responsible for multiple product launches and managing more than 80 employees in three sites and two countries.

Mr. Holmlin was a National Institutes of Health postdoctoral fellow at Harvard University, Cambridge, and a National Science Foundation predoctoral fellow at the California Institute of Technology, Pasadena (Caltech). He holds MBA degrees from the Haas School of Business at UC Berkeley and the Columbia University School of Business, earned his Ph.D. in chemistry at Caltech, and received his AB degree in chemistry at Occidental College, Los Angeles.

Listen to an interview with Erik



New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup